NATCO PHARMA LTD. - 524816 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Loss of Share Certificate intimation01-06-2023
01-06-2023
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Q4 FY23 Earnings Call Transcript01-06-2023
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation for the quarter and year ended 31st March, 202330-05-2023
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Earnings Call Audio recording link30-05-2023
NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Newspaper Publication
News Paper Publication copies30-05-2023
Natco Pharma Results Earnings Call for Q4FY23
Conference Call with Natco Pharma Management and Analysts on Q4FY23 Performance and Outlook. Listen to the full earnings transcript.30-05-2023
NATCO PHARMA LTD. - 524816 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Report for the year ended 31st March 202329-05-2023
NATCO PHARMA LTD. - 524816 - Related Party Transactions For The Half Year Ended March 31, 2023.
Related Party Transactions for the half year ended March 31, 2023.29-05-2023
Q4FY23 Quarterly & FY23 Annual Result Announced for Natco Pharma Ltd.
Pharmaceuticals company Natco Pharma announced Q4FY23 & FY23 results: Consolidated total revenue of Rs 2,811.7 crore for FY23, as against Rs 2,043.8 crore for FY22, reflecting 37.6% growth. The net profit for FY23, on a consolidated basis, was Rs 715.3 crore, as against Rs 170.0 crore in FY22. The increase in revenue and profits for FY23 was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil. Our Crop Health Division started off well with strong growth potential in ensuing years. For Q4FY23, the company recorded a net revenue of Rs 926.9 crore, on a consolidated basis, as against Rs 610.6 crore during Q4FY22. The profit for Q4FY23 on a consolidated basis was Rs 275.8 crore, as against a loss of Rs 50.5 crore in Q4FY22. Result PDF29-05-2023